Evidence map›Paper›PMID 39915589›Full record

ArticleCommunications biology2025

Expanding Yarrowia lipolytica's metabolic potential for detoxification of cyanogenic glycosides in edible plants.

Fidelis Azi, Zhiyu Li, Peng Xu

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fidelis AziDepartment of Chemical Engineering, Guangdong Technion-Israel Institute of Technology (GTIIT), Shantou, Guangdong, China.ORCID http://orcid.org/0000-0001-8986-5630
Zhiyu LiShandong Academy of Grape, Shandong Engineering Technology Research Centre of Viticulture and Grape, Jinan, China.
Peng XuDepartment of Chemical Engineering, Guangdong Technion-Israel Institute of Technology (GTIIT), Shantou, Guangdong, China. peng.xu@technion.ac.il.ORCID http://orcid.org/0000-0002-0999-8546

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22378083
6 · The paper itself

Abstract

Cyanides are highly toxic chemicals in several edible plants that threaten food safety and human health. A phenotypically distinct Yarrowia lipolytica strain that efficiently detoxifies multiple cyanogenic glycosides from edible plants was constructed using a family 1 glycosyl-hydrolase (GH1). The strain displayed higher growth rates and metabolic activities when exposed to high concentrations of cyanides than the wild-type. It overexpressed genes that promoted the binding of molecular oxygen to the cytochrome iv complex. The engineered strain repressed fatty acid production to optimize energy production and activated the cyanide-resistant respiratory (AOX) pathway to circumvent HCN toxicity and maintain cellular homeostasis. It upregulated ribosome biogenesis, the sec-dependent protein export pathway, and the sulfur relay system to facilitate the production and transmembrane efflux of the secreted GH1 hydrolase. It efficiently degraded linamarin, amygdalin, prunasin, and dhurrin in food plants including cassava, germinated sorghum and Apricot seeds. The strain produced high phospholipids to support new membrane production and could be a cost-effective source of single-cell phospholipids. The findings demonstrate that the strain is a robust, sustainable, and potentially efficient strain that could be used for industrial bioconversion of plant materials containing glycosylated toxicants into safe foods and animal feeds.

Indexed as

GlycosidesPlants, EdibleYarrowiaInactivation, Metaboliccyanogenic glycosidesGlycosides

Identifiers

PMID39915589
PMCPMC11802928

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.